𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

✍ Scribed by Awada, A; Hendlisz, A; Gil, T; Bartholomeus, S; Mano, M; de Valeriola, D; Strumberg, D; Brendel, E; Haase, C G; Schwartz, B

Book ID
109998514
Publisher
Nature Publishing Group
Year
2005
Tongue
English
Weight
138 KB
Volume
92
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase I Clinical and Pharmacokinetic Stu
Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors
✍ Strumberg, D. πŸ“‚ Article πŸ“… 2005 πŸ› American Society of Clinical Oncology 🌐 English βš– 207 KB

## Purpose BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors.